Clinical Trial Update: Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton [Phase 1]

View source ↗

Summary

This Phase 1 study reports safety and dosimetry data for Alpharadin (Radium-223 chloride) in hormone-refractory prostate cancer with bone metastases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Alpharadin (Radium-223 chloride)

Snippet

Sponsor: Bayer | Conditions: Prostate Cancer, Metastases | Phase 1 | Status: COMPLETED